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Abstract
Background: A large number of renal cancer patients shows poor or partial response to chemotherapy and the
mechanisms have not been still understood. Multi-drug resistance is the principal mechanism by which many
cancers develop resistance to chemotherapic drugs. The role of the multi-drug resistant transporter (MDR-1/P-
glycoprotein), the gene product of MDR-1, and that one of the so-called multi-drug resistance associated protein
(MRP), two energy-dependent efflux pumps, are commonly known to confer drug resistance.
We studied MDR-1 expression in selected cases of renal cell carcinoma (RCC), clear cell type, with long-term
follow-up, in order to establish its prognostic role and its possible contribution in the choice of post-surgical
therapy.
Methods:  MDR-1 has been studied by standard LSAB-HRP immunohistochemical technique, in paraffin
embedded RCC samples. Protein expression has been compared to clinical and histopathological data and to
disease specific survival of RCC patients, by Kaplan-Meier curve and Cox multivariate regression analyses.
Results: Two groups of RCCs were obtained by esteeming MDR-1 expression and disease specific survival
(obtained with Kaplan-Meier curve and Cox multivariate regression analyses): the first one presents low or absent
MDR-1 expression and good survival; the second one is characterized by high MDR-1 expression and significant
poor outcome (p < 0.05). Afterwards, we have found disease specific survival, adjusted for stages and independent
of therapy: this difference of survival rates was statistically significant (p < 0.05). Stage adjusted disease specific
survival rate, according to MDR-1 expression and therapy in patients affected by RCC in early stage (stage I), has
revealed that the group of patients with high MDR-1 expression and without adjuvant therapy showed poor
survival (p < 0.05). Cox multivariate regression analysis has confirmed that, in our cohort of RCC (clear cell type)
patients, the strong association between MDR-1 and worse outcome is independent not only of the adjuvant
therapy, but also of the other prognostic parameters (p < 0.05).
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Conclusion: In our opinion, the results of this study well prove the relationship between MDR-1 expression and
worse clinical prognosis in RCC, because MDR-1 over-expressing RCCs can be considered a group of tumours
with a more aggressive behavior. This finding outlines a possible role of MDR-1 as prognostic factor, dependent
and independent of multidrug resistance. These results could be useful to predict cancer evolution and to choose
the appropriate treatment: this is another step that can stimulate further promising and interesting investigations
on broader study population.
Background
Renal cancer is the seventh leading cause of cancer mortal-
ity, representing 2,6% of all human tumours [1]. The most
frequent type of renal cell carcinoma is the conventional
(clear cell) one [2]. Approximately, one third of the
patients with RCC has metastatic disease at the beginning,
and up to 50% relapses post-nephrectomy [3]. RCC is
characterized by a poor prognosis, almost unchanged for
decades, because of its late presentation and/or high
degree of intrinsic or acquired resistance to chemotherapy
[4].
The classical prognostic parameters, such as histological
grade and type, performance status, patient age, number
and site of metastases and their modality of appearance,
do not always assume an unequivocal role for the correct
management of RCC patients and to improve their clini-
cal outcome. Moreover, tumour biology of RCC still
remains poorly understood. So, the prognosis of the sin-
gle cases of RCC often persists as unpredictable [5-10].
It is well-known that renal cancer patients often show
poor or partial response to chemotherapy and the mecha-
nism is only partially known. Multi-drug resistance, the
principal mechanism by which many cancers develop
resistance to chemotherapy drugs, is one of the main fac-
tors in the failure of different chemotherapy protocols. It
affects patients with a variety of blood cancers and solid
tumours, including breast, ovary, lung and low gastroin-
testinal tract cancers. Resistance to therapy has been corre-
lated to the presence of, at least, two molecular "pumps"
that actively expel chemotherapics out of tumor cells: P-
glycoprotein and the multi-drug resistance associated pro-
tein (MRP) [11,12]. The multi-drug resistant transporter
(MDR-1/P-glycoprotein), the gene product of MDR-1, is a
glycosylated membrane protein of 170 kDa, belonging to
the ATP-binding cassette superfamily of membrane trans-
porters [12,13].
In the present study, we evaluated the role of MDR-1/P-
glycoprotein expression in a selected series of 30 conven-
tional (clear cell type) RCCs, in order to verify its value as
a predictor of clinical outcome.
Methods
Study population
A preliminary survey was performed on an initial renal
tumour population, represented by 30 RCCs (clear cell
type), 3 RCCs (sarcomatoid type), 2 RCCs (cromophobe
type), 1 RCC (papillary type) and 1 oncocytoma. Our
starting study was carried out on all these samples,
obtained from patients that underwent open-surgery at
the Department of Urology of the University "Federico II",
Naples, Italy, from January 1993 to December 1996. All
patients have been treated with radical open-nephrec-
tomy, including resection of peri-nephric fat, Gerota's fas-
cia, adrenal gland and regional lymph nodes. This first
research was directed to specify the most important prog-
nostic factors in renal neoplastic pathology: DNA ploidy
[14], anti and pro-apoptotic proteins (such as Bcl-2/Bcl-xl
and Bax), oncosuppressors (as p53), transporter proteins
(like MDR-1), thrombosis of caval vein, necrosis, multi-
centric pattern of growth, histotype, grading and staging.
By preliminary univariate analyses of the different his-
topathological, immunohistochemical and clinical
parameters, we could identify MDR-1 as the only immu-
nohistochemical factor and tumour stage as the sole his-
topathological parameter that were characterized by
values that were close to statistical significance. To stand-
ardize our study population, we selected only RCCs (clear
cell type) for the further investigations and we removed
the other histotypes because, in the initial sample, they
represented too small numerical fractions to be studied by
statistical analysis. Successively, Cox multivariate regres-
sion analysis (MVA) has been used to confirm independ-
ent predictors of outcome among histopathological,
immunohistochemical and clinical variables. Therefore,
30 RCCs (clear cell type) were employed in this following
study only when a complete and long-term clinical fol-
low-up was available. The mean follow-up time of the
studied cases was 69.83 months. All patients gave their
informed written consent and this study has been
approved by Ethical Committee of the University of
Naples.
Clinical data were reviewed to record sex, age of patients
and their follow-up status (Table 1).
The histopathological diagnosis of RCC was made at the
Department of Biomorphological and Functional Sci-BMC Cancer 2006, 6:293 http://www.biomedcentral.com/1471-2407/6/293
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ences, Section of Pathology, and confirmed at the Section
of Anatomic Pathology of the University of Foggia. Histo-
logical reports regard histotype, size, multicentric pattern
of growth, grade and stage, necrosis, thrombosis of caval
vein. Tumour extent, that, in the course of our previous
surveys, was defined by Robson system, in this study, has
been revised and classified according to the 2002 TNM
system [15-17], for the statistical analyses. Tumour
nuclear grade was defined using Fuhrman's histological
classification [18].
Immunohistochemistry
Tumour specimens for the immunohistochemical evalua-
tion with anti-MDR-1 protein were obtained from the
affected kidneys as described by Ljungberg et al. [14].
Briefly, for each formalin-fixed and paraffin-embedded
sample, 4-μm serial sections were cut, dewaxed and rehy-
drated. After quenching endogenous peroxidase, achiev-
ing antigen retrieval and blocking non-specific binding
sites, incubation with primary antibodies was carried out
overnight, at room temperature, with 1:100 dilution of
anti MDR-1 (polyclonal primary antibody, sc-1517, Santa
Cruz Biochemistry, Santa Cruz, CA). Finally, the bound-
ing of primary antibody was detected by the conventional
LSAB-HRP procedure, using DAB as chromogen.
Serial sections, on our RCC samples, also included non-
lesional areas, 5 cm distant from tumoral mass. Negative
controls were performed on these sections (the non-
lesional ones) and on other sections that comprised nor-
mal areas of removed kidneys for surgical non-neoplastic
renal diseases; while positive control was executed on sec-
tions obtained from a case of infiltrating breast cancer.
Slight nuclear counterstaining was realized with Harris'
haematoxylin.
The results of the immunohistochemical staining were
evaluated separately by two observers, completely una-
ware of the histological typing and of the follow-up data
of the single cases of RCC.
Synthetically, the number of MDR-1 expressing tumour
cells was estimated as a percentage of the final number of
cells per section and scored in three categories: score 1 (0–
20% of positive cells); score 2 (21–40% of MDR-1
expressing cells); score 3 (>40% of MDR-1 expressing
cells). The intensity of staining was graded as weak (+),
moderate (++), or strong (+++).
Absolute counts of immunostaining were made by scor-
ing neoplastic cells, selected among 7–8 non-consecutive
Table 1: Characteristics of study RCC (clear cell type) population. Table summarizes clinical data referring to patients' sex and age; 
notices about histological tumoral characteristics (such as thrombosis of caval vein, necrosis, multicentric pattern of growth and 
staging) and follow-up status have been reported, too.
Age
Range 44–83 Mean 59.8
Gender
Male 21 Female 9
Tumour Size
≤ 7 cm 17 > 7 cm 13
Thrombosis of caval vein
No 27 Yes 3
Necrosis
No 21 Yes 9
Multicentric pattern of growth
No 27 Yes 3
TNM 2002 Staging
T N 0N +M 0M +
T 1 a 6060
T 1 b 1 0 091
T 2 6161
T 3 a 3030
T 3 b 3030
T 3 c 0000
T 4 1010
Follow-up
Living patients Died from RCC patients Died from other causes 
patients
19 9 2
Table summarizes clinical data referring to patients' sex and age; notices about histological tumoral characteristics (such as thrombosis of caval vein, 
necrosis, multicentric pattern of growth and staging) and follow-up status have been reported, too.BMC Cancer 2006, 6:293 http://www.biomedcentral.com/1471-2407/6/293
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fields and chosen in the most viable areas of the lesions
(at ×40 magnification) [19,20].
Inter-rate reliability between the two investigators exam-
ining the immunostained sections was assessed by the
Cohen's K test, yielding K values higher than 0.70 in
almost all instances.
Statistical analysis
Data have been analyzed, utilizing GraphPad Prism ver-
sion 4 and SPSS version 15 statistical softwares. Multiple
observations are presented as arithmetic means with
standard errors of means. Statistical evaluations were car-
ried out using one way analysis of variance (ANOVA) and
the Student-Newman-Keuls test. The probabilities of dis-
ease specific survival were calculated by Kaplan Meier esti-
mates and Cox multivariate regression analysis. By this
last multivariate statistical evaluation, first of all, we ana-
lyzed the association between tumour stage (TNM 2002
staging system) and different clinical and histopathologi-
cal co-variables, controlling for sex, age, grading, tumour
size, multicentric pattern of growth, thrombosis of caval
vein, necrosis, adjuvant therapy and death from RCC.
Finally, the same relationships have been investigated for
MDR-1. Only values of p < 0.05 were considered as signif-
icant.
Results
Using x-ray, bone scan, liver ultrasound, abdominal com-
puted tomography and pathological reports, we deter-
mined TNM tumour extent of all cases, in replacement of
the former Robson staging system: 15 cases in stage I, 5 in
stage II, 7 in stage III and the last 3 in stage IV [21]. Fur-
thermore, 8 patients in stage I have been submitted to
adjuvant chemotherapy (Vinblastine 0.2–0.3 mg/Kg i.v.),
1 patient in stage II, 6 in stage III and nobody in stage IV.
From the histopathological examination, 6 out of 30
tumours were G1, 17 were G2, 4 were G3 and the remain-
ing ones were G4.
During the follow-up period of at least 5 years, 19 patients
remained tumour-free, 9 patients died from RCC, whereas
in 2 cases, death was independent of their renal cancer.
The statistical evaluation of immunohistochemical check-
ing has been compared with clinical reports, pathological
findings and follow-up data. There was no statistically sig-
nificant correlation between MDR-1 expression and sex,
age, tumour size, tumour stage and histological grade
(Table 2). On the other hand, we have obtained a statisti-
cally significant correlation between MDR-1 expression
and follow-up status: in 84% of the tumour-free patients,
the level of immunostaining displayed score 1 and, in the
remaining cases, 10% corresponds to score 2 and 6% to
score 3.
33% of patients who died from RCC showed score 3, 44%
score 2 and only 23% of them score 1. Two patients who
died from other diseases presented score 2 and 1, respec-
tively. Therefore, patients who died because of RCC or its
metastases had a higher score than patients still alive or
died from other causes.
In synthesis, the immunohistochemical analysis has
revealed, among all the selected cases, a weak positivity in
63% of them, a moderate positivity in 23% of the patients
and strong positivities in the remaining percentage of
cases. Afterwards, to obtain a precise survival analysis, it
has been possible to classify RCC patients in two different
groups, according to the MDR-1 expression grade (Figure
1): in this way, we have found that patients with moder-
ate-strong MDR-1 expression (score 2 – 3) had poorer sur-
vival rates, therefore a worse outcome, than the group of
patients with weak or absent immunostaining (score 1).
By the statistic Kaplan Meier curve (Figure 2), first of all we
have analysed clinical data, referring to disease specific
survival of RCC patients according to MDR-1 expression
(p < 0.05) and, subsequently, we have found disease spe-
cific survival, adjusted for stages and independent from
therapy (Figure 3). This difference of survival rates was sta-
tistically significant: patients in advanced stages had a
higher mortality than patients with localized RCC (p <
0.05).
Later on, to confirm the MDR-1 role as a real prognostic
factor in RCCs (clear cell type), apart from a chemo-resist-
ance marker, we excluded patients with a higher stage and
selected only patients in stage I (Figure 4): the fraction of
survival has statistically improved in RCCs treated with
adjuvant therapy and the high expression of MDR-1 has a
statistically significant correlation with a poorer progno-
sis, independently from using the adjuvant therapy (p <
0.05).
By Cox multivariate regression analysis (Table 3), we have
confirmed the relationship between advanced TNM 2002
stage (stage > I) and poor prognosis (p < 0.05). The corre-
lation between MDR-1 over-expression (score > 1) and
high mortality rate was statistically plain and significant
(p < 0.05), too (Table 4). Moreover, with respect to the
other co-variables (sex, age, death from RCC, grading,
tumour size, multicentric pattern of growth, thrombosis
of caval vein, necrosis, adjuvant chemotherapy), no statis-
tical association has been observed when tumour stage,
first, and MDR-1, then, had been considered as state vari-
ables.BMC Cancer 2006, 6:293 http://www.biomedcentral.com/1471-2407/6/293
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Discussion
The value of classic and modern prognostic factors in
renal clear cell carcinoma has been widely reported in the
literature. Tumour stage is the most important independ-
ent prognostic factor. The presence or absence of distant
metastases is highly prognostic and the presence of lymph
node metastases is of higher prognostic value than the
presence of renal vein invasion. For each given tumour
stage, tumour grade (especially nuclear grade) is the most
reliable additional independent prognostic factor predict-
ing patient survival [22]. The significance of DNA ploidy
as an independent prognostic factor is less clear, though it
might be useful in combination with nuclear grading [23].
Patient-related potential prognostic factors such as age,
sex and serologic parameters (thrombocytosis, erythro-
cyte sedimentation rate) are of lesser, if any, importance
[24].
Data from molecular analysis on oncogenes and suppres-
sor genes (p53), on angiogenetic factors (VEGFR), on
chromosomal aberration provide additional prognostic
information [25].
Considering RCC, there are still controversies about use of
particular markers as prognostic factors. So, remarkable
attention has been directed to the MDR-1 over-expression:
it is a widely studied phenomenon in a great number of
blood and solid tumours, in which it is responsible for the
resistance to chemotherapy.
The relationship between MDR-1 expression and progno-
sis in different tumour types is variable. In any case, it has
been elicited in numerous tumours [26].
MDR-1 is usually expressed in normal tissues including
the liver, kidney, small and large intestines, brain, testis,
muscle tissue, placenta and adrenals [27-33].
At the level of the luminal membrane of renal proximal
tubules, MDR-1 accelerates drug secretion into the urine.
Renal cell carcinoma derives from clonal cells lining the
Table 2: Statistical analysis of MDR-1 expression and associated clinic-pathological findings in RCCs. The statistical evaluation of 
immunohistochemical results has been compared to clinical reports, pathological findings and follow-up data. No statistically 
significant correlation between MDR-1 expression and sex, age, tumour size, tumour stage and histological grade has been obtained.
Variables N. Score 1 Score 2 Score 3 MEAN ± SEM
Cases 30 19 7 4
Age
< 65 years 20 12 5 3 1,55 ± 0,17
> 65 years 10 7 2 1 1,40 ± 0,22
Sex
Male 21 14 4 3 1,48 ± 0,16
F e m a l e 9531 1 , 5 6  ±  0 , 2 4
Tumour Size
≤ 7 cm 17 13 2 2 1,35 ± 0,17
> 7 cm 13 6 5 2 1,69 ± 0,21
Grading
G 1 6501 1 , 3 3  ±  0 , 3 3
G2 17 11 4 2 1,47 ± 0,17
G 3 – G 4 7331 1 , 7 1  ±  0 , 2 9
TNM Staging
I
(T1 N0 M0)
15 12 2 1 1,26 ± 0,15
II
(T2 N0 M0)
5221 1 , 8  ±  0 , 3 7
III
(T1 N1 M1)
(T2 N1 M0)
(T3 N0 M0)
(T3 N1 M0)
7421 1 , 5 7  ±  0 , 2 9
IV
(T4 N0 M0)
(T4 N1 M0)
(Any T Any N M+)
3111 2 , 0 0  ±  0 , 5 7
The statistical evaluation of immunohistochemical results has been compared to clinical reports, pathological findings and follow-up data. No 
statistically significant correlation between MDR-1 expression and sex, age, tumour size, tumour stage and histological grade has been obtained.
SEM: standard error of mean; Score 1 (0–20% of positive cells); Score 2 (21–40% of positive cells); Score 3 (≥ 40% of positive cells).BMC Cancer 2006, 6:293 http://www.biomedcentral.com/1471-2407/6/293
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luminal surface of the proximal tubule, which show an
intrinsic high level of expression of MDR-1 gene product.
This may explain the inborn MDR-1 mRNA expression in
RCC [34,35].
Although MDR-1 role in the pathogenesis of drug resist-
ance is clear, its role as a prognostic factor in RCC is still
doubtful.
In renal cell carcinoma, Duensing had already found a
longer progression-free survival in patients with no or very
few MDR-1 positive tumour cells compared to the group
of patients with higher MDR-1 positivity [36]. However,
this association was not confirmed by Oudard, who
showed a tendency for a lower MDR-1 expression in
advanced RCCs. From his point of view, this low level of
MDR-1 expression seems independent of the duration of
the disease [37].
In our study, we investigated the MDR-1 expression in all
RCCs evaluated. Only the cases of patients who died from
RCC showed the highest protein expression. Then, it is
possible to affirm that a strong MDR-1 level suggests a
poor outcome. MDR-1 seems to be an independent prog-
nostic factor in renal clear cell carcinoma, as confirmed by
Cox multivariate regression analysis.
Our results support the observation of Duensing et al.[36]
of a longer progression-free survival in patients with no or
very few MDR-1 positive tumour cells compared to the
group of patients with several positive tumour cells, but
are in disagreement with the report of Oudard et al.[37].
Immunohistochemical MDR-1 expression in RCCs Figure 1
Immunohistochemical MDR-1 expression in RCCs. Representative examples of RCCs with low (A: ×100; B: ×250) and 
high (C: ×400; D: ×400) MDR-1 expression, as evaluated by immunohistochemistry (LSAB-HRP, nuclear counterstaining with 
haematoxylin).BMC Cancer 2006, 6:293 http://www.biomedcentral.com/1471-2407/6/293
Page 7 of 10
(page number not for citation purposes)
Hofmockel had already noted that MDR-1 expression
seems to correlate with the differentiation of the RCC
[38]. Our study confirms the value of MDR-1 as prognos-
tic marker even if we have not obtained significant statis-
tical differences of MDR-1 expression among the various
histological grades.
As widely reported in literature, the importance of cancer
resistance depends, at least in part, on the MDR-1 expres-
sion, up-regulated by chemotherapy. In a previous work,
we had found a significant association between p53 over-
expression and the presence of an aggressive RCC pheno-
type [39].
Many experimental evidences prove that both p53 and
MDR-1 play decisive roles in chemo-resistance [13,40].
The relationship between MDR-1 and p53 is conditional,
that is, dependent on the cellular environment and drug
used. Mutation of p53 induces MDR-1 promoter transac-
tivation, resulting in an increased resistance to chemo-
therapy and radiation [13,41-43].
By this point of view, a gene therapy, based on wild type
p53, may result in a reduction of MDR-1 promoter expres-
sion and, overall, may confirm the idea of finding modu-
lators that could be able to inhibit the MDR-1 function
and, thereby, reverse multidrug resistance [13,44].
Precise determination of prognostic factors remains an
essential step in the evaluation of RCC patients.
Our study, carried out, however, on a fairly small cohort
of 30 RCC (clear cell type) patients with a long term fol-
low-up, has pointed out scientific interest on the specific
role of poor survival predictor that MDR-1 takes on, even
if we have considered only a single tumoral histotype.
Further investigations, maybe on larger and more hetero-
geneous population, should address to the relationship
between MDR-1 expression, renal carcinogenesis, neo-
plastic progression and degree of differentiation in RCC.
Anyhow, our results stimulate promising hypothesis and,
as for us, they may be useful not only to predict disease
evolution, but also to aid oncologists in the selection of
adjuvant post-surgical treatments.
Stage adjusted disease specific survival rate according to  MDR-1 expression and therapy in patient affected by RCC in  early stage (stage I) Figure 4
Stage adjusted disease specific survival rate accord-
ing to MDR-1 expression and therapy in patient 
affected by RCC in early stage (stage I). The group of 
patients with high MDR-1 expression without adjuvant ther-
apy showed poor survival (p < 0.05). This finding outlines a) 
the role of occult metastases at the time of diagnosis and b) 
confirms a possible role of MDR-1 as prognostic factor inde-
pendent of multidrug resistance.
Disease specific survival rate according to MDR-1 expression Figure 2
Disease specific survival rate according to MDR-1 
expression. The high expression patients showed a signifi-
cantly worse survival than low expression patients. Kaplan-
Meier analysis displays a significant result (p < 0.05).
Disease specific survival rate according to tumoral stage Figure 3
Disease specific survival rate according to tumoral 
stage. The advanced stages showed poorer survival (p < 
0.05).BMC Cancer 2006, 6:293 http://www.biomedcentral.com/1471-2407/6/293
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We must here remember that the failure to eradicate can-
cer may depend on a misidentification of the target. Cur-
rent therapies succeed at eliminating bulky disease but
often miss on a tumour reservoir that is the source of dis-
ease recurrence and metastases. Recent advances in the
understanding of tissue development cause us to revisit
the process of drug resistance, to apply it to oncogenesis
and tumour progression. According to the cancer stem cell
hypothesis, the renal cancer-initiating cell is a trans-
formed stem cell, which retains the essential property of
self-protection through the activity of multiple drug resist-
ance (MDR) transporters. This resting constitutively drug-
resistant cell remains at low frequency among a heteroge-
neous tumour mass. In the context of this hypothesis,
because conventional chemotherapy assures only limited
efficacy, the detection of MDR-1 diffusely over-expressing
RCCs may denote the need to choose patients to enroll in
new therapeutic trials, increasing the therapeutic index of
antineoplastic agents [35].
Conclusion
For years, an overflowing literature has been published
about MDR-1 gene expression in renal tumor cell lines at
various stages of disease and treatment. However, the clin-
ical significance of this particular protein, if it seemed
obvious in the past as a factor responsible for the develop-
ment of chemoresistance, is currently reconsidered. MDR-
1 gene expression seems to be, at least in some instances,
a hallmark of tumor cell aggressiveness, not only of chem-
oresistance. The failure of MDR-1 reversal trials might
result from this misunderstood role of MDR-1 expression
in cancer cells. In accordance to our investigations, MDR-
1 renal tumoral expression and worse clinical outcome
may be linked. This study has the aim to describe a new
role of MDR-1 and its clinical prognostic significance in
RCCs (clear cell type), suggesting that it could rather be
considered as an adverse prognostic factor, however inde-
pendent of therapy.
Table 3: Cox multivariate regression analysis: TNM tumour staging (stage I vs stages I, II, III, IV). 
Co-variables Significance (p)
Sex 0,613
Age* 0,715
Death from disease 0,004
Grading* 0,993
Tumour Size* 0,939
Multicentric Pattern of Growth 0,181
Thrombosis of caval vein 0,075
Necrosis 0,72
Adjuvant Therapy 0,783
We have considered tumour stage as state variable in correlation with different clinical and histopathological co-variables. The only significant 
statistical association has been observed between tumour stage and unfavourable outcome (p = 0.004).
*: for these co-variables, we have fixed the different cut-off values (≤ 65 years vs > 65 years for Age, G1 vs G2–G3–G4 for Grading, 7 cm vs > 7 cm 
as regards Tumour Size).
Table 4: Cox multivariate regression analysis: MDR-1 expression (score > 1 vs no expression). 
Co-variables Significance (p)
Sex 0,680
Age* 0,893
Death from disease 0,016
Grading* 0,627
Tumour Size* 0,842
Multicentric Pattern of Growth 0,380
Thrombosis of caval vein 0,372
Necrosis 0,378
Adjuvant Therapy 0,336
We have considered MDR-1 as state variable in correlation with different clinical and histopathological co-variables. The only significant statistical 
association has been noticed between MDR-1 expression and poorer prognosis (p = 0.016). MDR-1 expression seems to be a prognostic factor 
independent of adjuvant therapy (no significant p).
*: for these co-variables, we have fixed the different cut-off values (≤ 65 years vs > 65 years for Age, G1 vs G2–G3–G4 for Grading, ≤ 7 cm vs > 7 
cm as regards Tumour Size).BMC Cancer 2006, 6:293 http://www.biomedcentral.com/1471-2407/6/293
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